Has medical innovation reduced cancer mortality?

CESifo Economic Studies

Volumn 60, Issue 1, 2014, Pages 135-177

  Lichtenberg, Frank R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Cancer; Chemotherapy; Diagnostic imaging; Innovation; Longevity; Mortality; Neoplasm; Radiation; Surgery

Indexed keywords

CANCER; CHEMOTHERAPY; IMAGING METHOD; INNOVATION; LONGEVITY; MEDICINE; MORTALITY; RADIATION EXPOSURE;

EID: 84896823964     PISSN: 1610241X     EISSN: 16127501     Source Type: Journal    
DOI: 10.1093/cesifo/ift014     Document Type: Article

References (34)

1. American Medical Association (2013), Applying for CPT® Codes https://www.ama-assn.org/ama/pub/physician-resources/solutions-manag ing-your-practice/coding-billing-insurance/cpt/applying-cpt-codes.page? (last accessed 1 November 2013).
2. American Society for Radiation Oncology (2013), History of Radiation Therapy, http://www.rtanswers.com/aboutus/history.aspx (last accessed 1 November 2013).
3. Australian Productivity Commission (2005), Impacts of Advances in Medical Technology in Australia, Research Report, Melbourne, http://www.pc.gov.au/_data/assets/pdf_file/0003/17193/medicaltechnology.pdf (last accessed 1 November 2013).
4. Bradley, W. G. (2008), "History of Medical Imaging", Proceedings of the American Philosophical Society 152, 349-61.
5. Center for Medicare and Medicaid Services (2013a), National Health Expenditure Data, http://www.cms.gov/Research-Statistics-Data-and- Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/ Downloads/tables.pdf (last accessed 1 November 2013).
6. Center for Medicare and Medicaid Services (2013b), HCPCS -General Information, http://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/index.html?redirect=/medhcpcsgeninfo/(last accessed 1 November 2013).
7. Chabner, B. A. and T. G. Roberts, Jr (2005), "Timeline: Chemotherapy and the War on Cancer", Nature Review Cancer 5, 65-72.
8. Congressional Budget Office (2008), Technological Change, and the Growth of Health Care Spending, January, http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/89xx/doc8947/01-31-techhealth.pdf (last accessed 1 November 2013).
9. DeVita, V.T.Jr, and E. Chu (2008), "A History of Cancer Chemotherapy", Cancer Research 68, 8643-53.
10. Dorsey, E. R., J. de Roulet, J. P. Thompson, J. I. Reminick, A. Thai, Z. White-Stellato, C. A. Beck, B. P. George, and H. Moses, III (2010), "Financial Anatomy of Biomedical Research, 2003-2008", Journal of the American Medical Association 303, 137-43.
11. Feinstein, A. R., D. M. Sosin, and C. K. Wells (1985), "The Will Rogers Phenomenon. Stage Migration, and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer", New England Journal of Medicine 312, 1604-8.
12. Galiani, S., P. Gertler, and E. Schargrodsky (2005), "Water for Life: The Impact of the Privatization of Water Services on Child Mortality", Journal of Political Economy 113, 83-120.
13. Grossman, G. M., and E. Helpman (1991), "Quality Ladders in the Theory of Growth", The Review of Economic Studies 58, 43-61.
14. Harper, M. J. (2007), "Technology, and the Theory of Vintage Aggregation", in E. R. Berndt, and C. R. Hulten, eds., Hard-to-Measure Goods, and Services: Essays in Honor of Zvi Griliches, University of Chicago Press, Chicago, pp. 99-120, http://www.nber.org/chapters/c0875 (last accessed 1 November 2013).
15. Jalan, J., and M. Ravallion (2001), "Does Piped Water Reduce Diarrhea for Children in Rural India? World Bank Development Research Group", Policy Research Working Paper 2664, http://www1. worldbank.org/prem/poverty/ie/dime_papers/332.pdf (last accessed 1 November 2013).
16. Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman, and T. J. Philipson (2010), "An Economic Evaluation of the War on Cancer", Journal of Health Economics 29, 333-46.
17. Lichtenberg, F. R. (2008), "Pharmaceutical Innovation, and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data", Forum for Health Economics, and Policy 10 (Frontiers in Health Policy Research), Article 1.
18. Lichtenberg, F. R. (2009a), "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978-2004", Economics of Innovation, and New Technology 18, 407-28.
19. Lichtenberg, F. R. (2009b), "International Differences in Cancer Survival Rates: the Role of New Drug Launches", International Journal of Healthcare Technology, and Management 10, 138-55.
20. Lichtenberg, F. (2011), "The Quality of Medical Care, Behavioral Risk Factors,, and Longevity Growth", International Journal of Health Care Finance, and Economics 11, 1-34.
21. Mariotto, A. B., K. R. Yabroff, Y. Shao, E. J. Feuer, and M. L. Brown (2011), "Projections of the Cost of Cancer Care in the United States: 2010-2020", Journal of the National Cancer Institute 103, 117-28, http://www.natap.org/2010/newsUpdates/NatlCancerMariotto.pdf (last accessed 1 November 2013).
22. Murphy, K. M., and R. H. Topel (2006), "The Value of Health, and Longevity", Journal of Political Economy 114, 871-904.
23. National Cancer Institute (2013a), Cancer Costs Projected to Reach at Least $158 Billion in 2020, http://www.cancer.gov/newscenter/news fromnci/2011/CostCancer2020 (last accessed 1 November 2013).
24. National Cancer Institute (2013b), The Cost of Cancer, http://www. cancer.gov/aboutnci/servingpeople/cancer-statistics/costofcancer (last accessed 1 November 2013).
25. National Cancer Institute (2013c), Uses of Imaging -Cancer Imaging Program http://imaging.cancer.gov/patientsandproviders/cancerimaging/usesofimaging (last accessed 1 November 2013).
26. National Science Foundation (2013), U.S. Corporate R&D: Volume 1: Top 500 Firms in R&D by Industry Category, http://www.nsf.gov/statistics/nsf00301/expendit.htm (last accessed 1 November 2013).
27. Nobelprize.org (2013), The Prize in Economics 1987 -Press Release, http://www.nobelprize.org/nobel_prizes/economics/laureates/1987/press.html (last accessed 1 November 2013).
28. Sampat, B. N., and F. R. Lichtenberg (2011), "What are the Respective Roles of the Public, and Private Sectors in Pharmaceutical Innovation?", Health Affairs 30, 332-9.
29. Solow, R. M. (1960), "Investment, and Technological Progress", in K. Arrow, S. Karlin, and P. Suppes, eds., Mathematical Methods in Social Sciences 1959, Stanford University Press, Stanford, pp. 89-104.
30. Stukel, T. A., E. S. Fisher, D. E. Wennberg, D. A. Alter, D. J. Gottlieb, and M. J. Vermeulen (2007), "Analysis of Observational Studies in the Presence of Treatment Selection Bias: Effects of Invasive Cardiac Management on AMI Survival Using Propensity Score, and Instrumental Variable Methods", JAMA 297, 278-85, http://jama.jamanetwork. com/article.aspx?articleid=205172 (last accessed 1 November 2013).
31. Thaul, S.(2012), "How FDA Approves Drugs, and Regulates Their Safety, and Effectiveness", Congresional Research Service, June 25, http://www.fas.org/sgp/crs/misc/R41983.pdf (last accessed 1 November 2013).
32. Tseng, V., F.Yu, F.Lum, and A.Coleman (2012), "Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries", JAMA 308, 493-501.
33. Wooldridge, J.M.(2009), Introductory Econometrics: A Modern Approach, 4e (Cengage Learning).
34. Yabroff, K.R., E.B.Lamont, A.Mariotto, J.L.Warren, M.Topor, A.Meekins, and M.L.Brown (2008), "Cost of Care for Elderly Cancer Patients in the United States", Journal of National Cancer Institute 100, 630-41, http://jnci.oxfordjournals.org/content/100/9/630.full (last accessed 1 November 2013).